Quest Diagnostics

Current directors and officers who also hold a role at another S&P 500 company.

• Denise M. MorrisonMET · DirectorV · Director
• Sam SamadIDXX · Director
• Timothy M. RingBDX · Director
• Tracey DoiPNR · Director
• Wright Lassiter IIIFTV · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 6, 2026

   On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027. Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, the Company’s multi-year project to modernize its “Order to Cash” business processes, which includes the related information technology infrastructure and underlying enabling technologies. In connection with this transition, the Company’s Compensation and Leadership Development Committee (the “Committee”) approved no change to Ms. Doherty’s annual base salary of $650,000 or annual incentive compensation under the Company's Senior Management Incentive Plan with a target amount of 80% of base salary.

   Read the 8-K filing
2. Mar 12, 2026

   (d) On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board’s Compensation and Leadership Development Committee and the Board’s Quality and Compliance Committee. The Board determined that Mr. Wentworth is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its corporate governance guidelines. Mr. Wentworth will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices. As part of that compensation, Mr.

   Read the 8-K filing
3. May 21, 2024

   (d) On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board. Mr. Carter is the Executive Vice President, Chief Information Officer of FedEx Corporation and Co-President and Co-CEO of FedEx Services. The Board determined that Mr. Carter is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its Corporate Governance Guidelines, which are available on the Company’s website. Mr. Carter’s membership on any Committee of the Board has not been determined at this time. Mr. Carter will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices.

   Read the 8-K filing
4. Sep 29, 2023

   (b) On September 28, 2023, Gail R. Wilensky, Ph.D. informed Quest Diagnostics Incorporated (the “Company”) of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders expected to be held May 2024 (the “2024 Annual Stockholders Meeting”), and to retire from the Board effective as of the date of the 2024 Annual Stockholders Meeting, when her current term as a director expires.

   Read the 8-K filing
5. Nov 18, 2022

   e. On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan"). A copy of the Plan with an updated Schedule B is attached as Exhibit 10.1 and is incorporated herein by reference.

   Read the 8-K filing
6. Nov 1, 2022

   (c) (d) On October 31, 2022, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”) increased the Board’s size from 9 to 10 directors and elected James E. Davis to fill the resulting vacancy effective November 1, 2022. Mr. Davis is not party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. On November 1, 2022, the Company issued a press release announcing that Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company, in each case effective November 1, 2022. A copy of the press release announcing this information is furnished herewith as Exhibit 99.1.

   Read the 8-K filing
7. Oct 28, 2022

   (e) On October 28, 2022, the Compensation Committee (the “Committee”) of the Board of Directors of Quest Diagnostics Incorporated (the “Company”) approved an updated compensation package for Mr. Davis, reflecting Mr. Davis becoming Chief Executive Officer and President of the Company. Effective November 1, 2022: (i) Mr. Davis’ base salary was increased to an annual rate of $1,100,000; (ii) his target annual incentive under the Company’s Senior Management Incentive Plan was increased to 150% of his annual base salary rate (for 2022, his annual incentive award will be pro-rated to reflect his service as CEO-Elect and thereafter as Chief Executive Officer and President); (iii) Mr. Davis will become a Schedule A Participant (rather than a Schedule B Participant) in the Company’s Executive Officer Severance Plan; (iv) Mr.

   Read the 8-K filing
8. Jul 1, 2022

   In connection with his retirement, Mr. Rusckowski’s existing employment agreement with the company will not be renewed, pursuant to notice given in accordance with the employment agreement on June 29, 2022. Mr. Rusckowski’s compensation for his service as Executive Chairman will generally be aligned with his 2022 compensation .

   Read the 8-K filing
9. Jun 14, 2022

   (c), (e) On June 9, 2022, Quest Diagnostics Incorporated (the “Company”) announced that Sam Samad will become Executive Vice President and Chief Financial Officer of the Company. Mr. Samad will join the Company on July 11, 2022 and become Chief Financial Officer on July 25, 2022. Mr. Samad succeeds Mark Guinan, who, in February 2022, announced his decision to retire. Mr. Samad, age 52, has served since 2017 as Chief Financial Officer of Illumina, Inc., a publicly-held company that is a global leader in DNA sequencing and array-based technologies. Previously, he served in a variety of senior roles at Cardinal Health, including most recently as Senior Vice President and Corporate Treasurer, with operational and financial responsibility for Cardinal Health’s China business. Prior to that, Mr.

   Read the 8-K filing
10. May 25, 2022

    b. Quest Diagnostics Incorporated (the “Company”) announced that Carrie Eglinton Manner, the Company’s Senior Vice President, Advanced and General Diagnostics and Clinical Solutions, resigned from the Company effective June 3, 2022 to join OraSure Technologies, Inc.

    Read the 8-K filing
11. Mar 2, 2022

    On February 24, 2022, Dr. Helen I. Torley informed the Company of her decision to not seek re-election to the Company’s Board of Directors (the “Board”) at the Company’s Annual Meeting of Stockholders to be held May 18, 2022 (the “Annual Meeting”). Dr. Torley, who is President and CEO of Halozyme Therapeutics, informed the Company that she desires to focus on board service for companies developing innovative medicines. In connection with Dr. Torley’s decision, the Board approved a reduction in the size of the Board, from 10 directors to 9, effective at the Annual Meeting.

    Read the 8-K filing
12. Mar 1, 2022

    On February 24, 2022, the Compensation Committee of the Board of Directors of the Company approved the following compensation for Mr. Davis for 2022: an annual base salary (“Base Salary”) of $800,000; a target cash incentive compensation award (“Annual Bonus”) of 100% of Base Salary; and a target long-term incentive award (“LTI Award”) for 2022 with a grant date fair value of $4,880,649. Mr. Davis’s Annual Bonus is made pursuant to the Company’s Senior Management Incentive Plan and Mr. Davis’s LTI Award is made pursuant to the Company’s Amended and Restated Employee Long-Term Incentive Plan. The LTI Award consists of 50% performance shares (3-year performance period), 25% stock options and 25% restricted stock units.

    Read the 8-K filing
13. Mar 1, 2022

    On February 24, 2022, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Company approved a special equity grant for Carrie Eglinton Manner, the Company’s Senior Vice President, Advanced Diagnostics, with the purpose of promoting the success of the Company’s management succession plan and to incent Ms. Eglinton Manner to achieve growth in revenues associated with the service offerings for which she has management responsibility in the Company’s Diagnostic Information Services business. The grant has a grant date fair value of $1,940,235 and was made pursuant to the Company’s Amended and Restated Employee Long-Term Incentive Plan. The grant consists of 50% performance shares and 50% restricted stock units, and does not provide for accelerated vesting upon qualifying retirement.

    Read the 8-K filing
14. Feb 3, 2022

    On February 3, 2022, the Company announced that its Board of Directors (the "Board"), as part of its ongoing leadership succession planning, has appointed James E. Davis, currently Executive Vice President, General Diagnostics, to be its next Chief Executive Officer and President, effective November 1, 2022. In addition, Mr. Davis was appointed Chief Executive Officer – Elect, effective February 3, 2022. On November 1, 2022, Mr. Davis will succeed Stephen H. Rusckowski, who will have served as Chief Executive Officer and President for more than a decade. Mr. Rusckowski, 64, currently Chairman, Chief Executive Officer and President, will continue to serve on the Board as Executive Chairman through March 2023. Mark J. Guinan, the Company’s Executive Vice President and Chief Financial Officer, will retire in 2022. The Company has begun a search to identify Mr. Guinan’s successor. Mr.

    Read the 8-K filing
15. Aug 19, 2021

    (d) On August 16, 2021, the Board increased its size from 9 to 10 directors. After considering the recommendation of the Board's Governance Committee, the Board elected Tracey C. Doi, Chief Financial Officer and Group Vice President of Toyota Motor North America, to fill the resulting vacancy, effective immediately. The Board determined that Ms. Doi is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its corporate governance principles. The Board appointed Ms. Doi to serve on the Board’s Audit and Finance and Cybersecurity Committees. Ms. Doi will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described in the Company’s proxy statement for its annual meeting of stockholders, filed April 8, 2021.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.